Opendata, web and dolomites


Advancing cancer immunotherapy using natural killer cells for hematological and metastatic cancers

Total Cost €


EC-Contrib. €






 CINK project word cloud

Explore the words cloud of the CINK project. It provides you a very rough idea of what is the project "CINK" about.

ing    intensively    impacted    explore    evasion    limited    therapies    molecule    date    combining    nca    suppression    mechanisms    activation    ab    intrinsic    expanded    immunregulatory    benefit    translated    limiting    time    clinic    signals    stimulating    binding    expression    stem    cellular    shp1    anti    cd137    blockade    coated    costimulation    cancer    frame    inhibitory    shown    strategies    cytotoxicty    express    lymphomas    hematological    negatively    treatment    types    adoptive    tumor    therapy    portion    action    hsct    dependent    antibodies    metastatic    multiple    transfer    cancers    transplantation    relapse    tremendously    rates    hypothesize    monoclonal    unstable    versatility    aggressive    mab    potentially    stronger    ncf    il12    efficacy    cell    function    hematopoietic    cd16    leukemias    induction    limits    heterogeneity    combination    sustained    fc    adcc    amount    immunotherapy    myeloma    improvement    nk    explored    consequently    cells    combine    antibody   

Project "CINK" data sheet

The following table provides information about the project.


Organization address
address: AVENIDA DE PIO XII 55
postcode: 31008

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-02-15   to  2020-02-14


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

The development of monoclonal antibodies (mAb) to target tumor cells has tremendously improve cancer immunotherapy and benefit the treatment of aggressive cancer such as some types of lymphomas, leukemias, multiple myeloma and metastatic cancers. One of the mechanisms of action is the induction of antibody-dependent cellular cytotoxicty (ADCC) through the activation of CD16 on NK cells after binding to the Fc portion of Ab-coated tumor cells. Therefore, strategies that combine NK cell activation and mAb therapy has been intensively explored. However, tumor heterogeneity and unstable expression of the targeted molecule in the tumor cells limits ADCC for mAb therapy resulting in cancer relapse. Furthermore, intrinsic NK immunregulatory mechanisms as well as NK-specific tumor evasion mechanisms have also negatively impacted the use of NK cell-based therapies. In this proposal we will explore the mechanisms involved in the reduced NK cell function (NCF) observed after ADCC and/or NK cell activation (NCA) in order to develop novel strategies to achieve a sustained and stronger NCF by combining stimulating signals with suppression of inhibitory signals such as costimulation via CD137 and IL12, or SHP1/2 blockade. We hypothesize that the adoptive transfer (AT) of NK cells expanded by this novel method will result in better anti-tumor responses after mAb therapy even in tumor cells that express limited amount of the target molecule and limiting consequently cancer relapse rates. Furthermore, due to the overall improvement on NCF, we expect that the combination of AT NK cells with hematopoietic stem cell transplantation (HSCT) will also increase anti-tumor responses; which efficacy up to date has shown to be rather limited. Given the versatility of our approach, this therapy can be used for the treatment of many cancers, but particularly hematological and metastatic cancers and potentially can be translated into the clinic in a short time frame.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CINK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CINK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

DEMOS (2019)

Disfluencies and Eye MOvements during Speech: what can they reveal about language production?

Read More  

MathematicsAnalogies (2019)

Mathematics Analogies

Read More  

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More